Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance in Advanced NSCLC (PIN)
NCT01788332Phase 2Unknown
- Start
- Jan 2014
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olaparib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 72 weeks. Status: unknown.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01788332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788332.